Skip to content
10-Q

Quarterly Report

European Biotech Acquisition Corp.

0001193125-22-151461

← back to feed
Filed
May 16, 2022 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Operating Cash Flow Q1 2022 · Mar 31, 2022 −$149.99K
Operating Cash Flow Q1 2022 · Mar 31, 2021 −$15.06K
Cash And Equivalents Q1 2022 · Mar 31, 2022 $718.29K
Cash And Equivalents Q1 2022 · Dec 31, 2021 $868.28K
Stockholders Equity Q1 2022 · Mar 31, 2022 −$5.18M
Stockholders Equity Q1 2022 · Dec 31, 2021 −$6.69M
Stockholders Equity restated Q1 2022 · Mar 31, 2021 −$7.36M
Stockholders Equity Q1 2022 · Jan 7, 2021 $0
Current Liabilities Q1 2022 · Mar 31, 2022 $528.91K
Current Liabilities Q1 2022 · Dec 31, 2021 $505.2K
Total Liabilities Q1 2022 · Mar 31, 2022 $6.15M
Total Liabilities Q1 2022 · Dec 31, 2021 $7.61M
Current Assets Q1 2022 · Mar 31, 2022 $948.52K
Current Assets Q1 2022 · Dec 31, 2021 $916.47K
Total Assets Q1 2022 · Mar 31, 2022 $128.52M
Total Assets Q1 2022 · Dec 31, 2021 $128.47M
Sga Expense Q1 2022 · Mar 31, 2022 $203.27K
Sga Expense Q1 2022 · Mar 31, 2021 $89.85K
Net Income Q1 2022 · Mar 31, 2022 $1.51M
Net Income Q1 2022 · Mar 31, 2021 $254.84K
Operating Income Q1 2022 · Mar 31, 2022 −$263.27K
Operating Income Q1 2022 · Mar 31, 2021 −$109.85K